Glycemic responses differ by exercise classification (i.e. aerobic, interval, resistance) in individuals with T1D, but the impact of insulin delivery modality (multiple daily injections [MDI], pump, closed loop) on these differences is unclear. Data from the Type 1 Diabetes Exercise Initiative study allowed us to compare glycemic responses by insulin delivery method. Adults (N=497) with T1D ([mean ± SD] age= 37 ± 14 years; HbA1C= 6.6 ± 0.8%) were assigned to complete six at-home sessions of aerobic, interval, or resistance exercise over 4 weeks, using study-developed instructional videos approximately 30 minutes in duration. Mean [95% CI] change in glucose during the assigned exercise was -[95% CI -22, -16], -15 [-18, -12], and -9 [-12, -7] mg/dL for aerobic, interval, and resistance exercise, respectively (P<0.001) , after adjusting for baseline glucose, insulin delivery modality, age, and sex. This pattern was similar irrespective of insulin delivery modality (Figure) .

In summary, regardless of insulin delivery modality, adults with T1D experienced the largest glucose drop for aerobic exercise followed by interval exercise and resistance exercise.

graphic
View largeDownload slide
Disclosure

M.Riddell: Advisory Panel; Zealand Pharma A/S, Zucara Therapeutics, Consultant; Eli Lilly and Company, Jaeb Center for Health Research, Speaker's Bureau; Dexcom, Inc., Eli Lilly and Company, Novo Nordisk. P.Calhoun: None. J.R.Castle: Advisory Panel; Insulet Corporation, Novo Nordisk, Zealand Pharma A/S, Stock/Shareholder; Pacific Diabetes Technologies. R.Beck: Consultant; Diasome, Eli Lilly and Company, Insulet Corporation, Novo Nordisk, Research Support; Ascensia Diabetes Care, Beta Bionics, Inc., Bigfoot Biomedical, Inc., Dexcom, Inc., Eli Lilly and Company, Medtronic, Novo Nordisk, Roche Diabetes Care, Tandem Diabetes Care, Inc. M.R.Rickels: Advisory Panel; Sernova, Corp., Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S, Consultant; L-Nutra Inc. S.R.Patton: None. C.K.Martin: Advisory Panel; Wondr Health, Board Member; EHE Health, Other Relationship; ABGIL, ABGIL, Academy of Nutrition and Dietetics. Z.Li: None. P.G.Jacobs: Other Relationship; Pacific Diabetes Technologies, Research Support; Dexcom, Inc. M.B.Gillingham: None. R.L.Gal: None. F.J.Doyle: Other Relationship; Dexcom, Inc., Insulet Corporation, Roche Diabetes Care, Stock/Shareholder; Mode AGC. M.A.Clements: Consultant; Glooko, Inc., Research Support; Abbott Diabetes, Dexcom, Inc.

© 2022 by the American Diabetes Association
2022
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.